DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksSchließen
Referenz
Colao A, Zgliczyński W, Komorowski J. et al.
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Endokrynol Pol 2019;
70: 305-312
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.